BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicity.
Margaux PoussardLaure Philippe WalterMaxime FredonElodie Bôle-RichardSabeha BiichleFlorian RenosiSophie PerrinMarie KroemerSamuel LimatFrancis BonnefoyEtienne DaguindauErick DeconinckBérengère GrusonPhilippe SaasOlivier AdotéviFrancine Garnache-OttouFanny Angelot-DelettrePublished in: EJHaem (2020)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these therapies, the influence of one on the other has to be explored. We set up a model to test the combination of polychemotherapy - named methotrexate, idarubicine, dexamethasone, and L-asparaginase (MIDA) - and CD123 CAR-T cell therapy. We showed that CD123 CAR-T cells exert the same effect on BPDCN models alone, or after MIDA regimen. These data support a preclinical rationale to use immunotherapy after a treatment with polychemotherapy for BPDCN patients.
Keyphrases
- dendritic cells
- cell therapy
- poor prognosis
- long non coding rna
- end stage renal disease
- newly diagnosed
- stem cell transplantation
- ejection fraction
- chronic kidney disease
- immune response
- nk cells
- bone marrow
- mesenchymal stem cells
- low dose
- regulatory t cells
- clinical trial
- squamous cell carcinoma
- low grade
- combination therapy
- radiation therapy
- machine learning
- smoking cessation
- artificial intelligence
- hematopoietic stem cell
- chemotherapy induced